Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction

DOI 被引用文献1件
  • Jawad H. Butt
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom, and Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark (J.H.B.)
  • Pooja Dewan
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (P.D., K.F.D., P.S.J., J.J.V.M.)
  • Béla Merkely
    Heart and Vascular Centre, Semmelweis University, Budapest, Hungary (B.M.)
  • Jan Belohlávek
    Second Department of Internal Medicine, Cardiovascular Medicine, General Teaching Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic (J.B.)
  • Jarosław Drożdż
    Department of Cardiology, Medical University of Lodz, Lodz, Poland (J.D.)
  • Masafumi Kitakaze
    Cardiovascular Division of Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan (M.K.)
  • Silvio E. Inzucchi
    Section of Endocrinology, Yale School of Medicine, New Haven, Connecticut (S.E.I.)
  • Mikhail N. Kosiborod
    Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City, Missouri, and The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia (M.N.K.)
  • Felipe A. Martinez
    Universidad Nacional de Córdoba, Córdoba, Argentina (F.A.M.)
  • Sergey Tereshchenko
    Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology of Russia, Moscow, Russia (S.T.)
  • Piotr Ponikowski
    Center for Heart Diseases, University Hospital, Wroclaw Medical University, Wroclaw, Poland (P.P.)
  • Olof Bengtsson
    Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., D.L., A.M.L., M.Sjöstrand)
  • Daniel Lindholm
    Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., D.L., A.M.L., M.Sjöstrand)
  • Anna Maria Langkilde
    Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., D.L., A.M.L., M.Sjöstrand)
  • Morten Schou
    Department of Cardiology, Herlev-Gentofte University Hospital, Herlev, Denmark (M.Schou)
  • Mikaela Sjöstrand
    Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., D.L., A.M.L., M.Sjöstrand)
  • Scott D. Solomon
    Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts (S.D.S.)
  • Marc S. Sabatine
    Division of Cardiovascular Medicine and TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts (M.S.S.)
  • Chern-En Chiang
    General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University, Taipei, Taiwan (C.C.)
  • Kieran F. Docherty
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (P.D., K.F.D., P.S.J., J.J.V.M.)
  • Pardeep S. Jhund
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (P.D., K.F.D., P.S.J., J.J.V.M.)
  • Lars Køber
    Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark (L.K.).
  • John J.V. McMurray
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (P.D., K.F.D., P.S.J., J.J.V.M.)

書誌事項

タイトル別名
  • A Post Hoc Analysis of the DAPA-HF Trial

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

  • CRID
    1360861710908263680
  • DOI
    10.7326/m21-4776
  • ISSN
    15393704
    00034819
  • データソース種別
    • Crossref

問題の指摘

ページトップへ